Overview

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Status:
Completed

Trial end date:
2017-12-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Capecitabine
Taxane